CIK 0001821825 · Pharmaceutical Preparations (SIC 2834) · NYSE · fiscal year ends 12/31
| FY2025 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|
| Revenue (USD) | 6.2 B | 6.3 B | ||
| Net income (USD) | 2.2 B | 3.2 B | ||
| Diluted EPS (USD/shares) | 0.72 | 5.31 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-08-14 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-08-12 | 4 | FORM 4 | 2026-08-11 |
| 2026-08-05 | 144 | 144 | |
| 2026-08-05 | 4 | FORM 4 | 2026-08-05 |
| 2026-07-31 | SCHEDULE 13G/A | SCHEDULE 13G/A | |
| 2026-07-31 | 8-K | FORM 8-K items 7.01,9.01 | 2026-07-31 |
| 2026-07-31 | 10-Q | 10-Q | 2026-06-30 |
| 2026-07-23 | 8-K | 8-K items 5.07 | 2026-07-23 |
| 2026-07-17 | DEFA14A | DEFA14A | |
| 2026-07-17 | 8-K | 8-K items 8.01 | 2026-07-17 |
| 2026-06-17 | DEFM14A | DEFM14A | |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-15 | 4 | FORM 4 | 2026-06-12 |
| 2026-06-11 | 8-K | FORM 8-K items 5.02,5.07,9.01 | 2026-06-09 |
| 2026-06-11 | DEFA14A | DEFA14A | |
| 2026-06-01 | PREM14A | PREM14A | 2026-05-29 |
| 2026-05-29 | SD | FORM SD | |
| 2026-05-08 | 144 | 144 |
Forms on file (last 1,000): 4 282, 8-K 47, 3 33, 10-Q 17, DEFA14A 13, SC 13G/A 8, UPLOAD 6, DEF 14A 5. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=OGN (0.002 USD), /gw/filings/filings?ticker=OGN&form=8-K, /gw/filings/facts?ticker=OGN&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange